Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

Phase 2 Completed NCT01649765

Condition	Systemic Lupus Erythematosus
Phase	Phase 2
Sponsor	GlaxoSmithKline
Status	Completed
Enrollment	93 participants
Interventions	Belimumab 10 mg/kg
Start date	Sep 7, 2012
Completion date	Jan 24, 2018
Results posted	Aug 15, 2018

Summary

This is a multi-center study to evaluate the safety, pharmacokinetics, and efficacy of belimumab intravenous (IV) in pediatric patients 5 to 17 years of age with active systemic lupus erythematosus

Percentage of Participants With SLE Responder Index (SRI) Response at Week 52

Week 52 · Percentage of participants

Part A: Placebo	43.6 Percentage of participants
Part A: Belimumab 10 mg/kg	52.8 Percentage of participants

Odds Ratio (OR)	1.49 (95% CI 0.64–3.46)

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacok — Viatris Innovation GmbH
Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With — Viatris Innovation GmbH
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2 — Hoffmann-La Roche
Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults — Duke University
Reducing Disparities in Medication Adherence in SLE — Duke University
Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pa — Northwell Health

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский